About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Chiome Bioscience Inc.(4583) Summary

4583
TSE Growth
Chiome Bioscience Inc.
128
JPY
+7
(+5.79%)
Apr 10, 10:50 am JST
0.87
USD
Apr 9, 9:50 pm EDT
Result
PTS
outside of trading hours
127.8
Apr 10, 10:49 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.54
Yield
ー%
Margin Trading Ratio
946.00
Stock Price
Apr 10, 2025
Opening Apr 10, 9:06 am
132 JPY 0.89 USD
Previous Close Apr 9
121 JPY 0.83 USD
High Apr 10, 9:06 am
134 JPY 0.90 USD
Low Apr 10, 10:13 am
127 JPY 0.86 USD
Volume
1,131,100
Trading Value
0.15B JPY 1.00M USD
VWAP
129.91 JPY 0.88 USD
Minimum Trading Value
12,800 JPY 87 USD
Market Cap
8.67B JPY 0.06B USD
Number of Trades
358
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
1,597
1-Year High Nov 26, 2024
45,181
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 8,160,300
Mar 28, 2025 0 9,493,000
Mar 21, 2025 0 9,571,400
Mar 14, 2025 0 9,089,400
Mar 7, 2025 0 9,259,300
Company Profile
Chiome Bioscience Inc. is a drug discovery venture originating from RIKEN. The company specializes in proprietary antibody production technology and generates revenue through licensing.
Sector
Pharmaceuticals
Chiome Bioscience Inc. focuses on developing drug candidates for diseases with high unmet medical needs and supporting antibody drug discovery research, utilizing its core proprietary antibody production technology, the ADLib system. The company's main business area covers upstream processes from basic and exploratory research to preclinical development and early clinical development, with a basic strategy of early out-licensing of development candidate antibodies. In its drug discovery support business, Chiome Bioscience Inc. offers protein expression and purification services as well as antibody production services. The company integrates multiple antibody production technologies to maximize its antibody production capabilities. Chiome Bioscience Inc. has several in-house pipelines, including CBA-1205 and CBA-1535, and is actively promoting new drug discovery projects.